Lexaria Bioscience Corp. (LEXX)
| Market Cap | 9.08M -58.2% |
| Revenue (ttm) | 194,000 -68.5% |
| Net Income | -7.73M |
| EPS | -5.14 |
| Shares Out | 2.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,275 |
| Open | 4.300 |
| Previous Close | 4.640 |
| Day's Range | 4.020 - 4.340 |
| 52-Week Range | 2.430 - 21.600 |
| Beta | 0.58 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About LEXX
Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules, including ... [Read more]
Financial Performance
In fiscal year 2025, Lexaria Bioscience's revenue was $705,923, an increase of 52.05% compared to the previous year's $464,278. Losses were -$11.90 million, 105.4% more than in 2024.
Financial StatementsNews
Lexaria Bioscience enters new pharmaceutical agreement for DehydraTECH
Lexaria Bioscience (LEXX) announces that it has entered into an Agreement with an unnamed pharmaceutical company to investigate Lexaria’s DehydraTECH technology with one or more proprietary PharmCo mo...
Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH
Third pharmaceutical company relationship entered Kelowna, British Columbia – November 4, 2026 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the “ Company ” or “ Lexaria ”), a global inn...
Lexaria Bioscience announces 70th patent award
Lexaria Bioscience (LEXX) provides this update on additional new intellectual property granted to the Company as a result of its ongoing research and development, R&D, programs. The expansion of our…
Lexaria Celebrates its 70th Patent Award
New patents awarded in the US, Canada, and Europe IP protection for treatments for Epilepsy, Diabetes, and Hypertension
Lexaria Bioscience reaches full enrollment in GLP-1-H26-7 study
Lexaria Bioscience (LEXX) reports that full enrollment has been reached and dosing continues on schedule with Human Pilot Study #7 which is evaluating two oral DehydraTECH-semaglutide compositions aga...
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
Kelowna, BC – October 21, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, reports that full enrollment has been...
Lexaria Bioscience announces results from animal study GLP-1-A26-1
Lexaria Bioscience (LEXX) provides the following results from animal study GLP-1-A26-1 that evaluated a number of formulation enhancements using both DehydraTECH-CBD compositions and DehydraTECH-semag...
Lexaria Announces Results from Animal Study GLP-1-A26-1
Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD KELOWNA, BC / ACCESS Newswire / October 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"),...
Lexaria Announces Results From Animal Study GLP-1-A26-1
Results highlighted by a 566% improvement in brain absorption of DehydraTECH-CBD Kelowna, BC – October 15, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), ...
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery KELOWNA, BC / ACCESS N...
Lexaria Bioscience Registration statement: Registration filing
Lexaria Bioscience filed a registration statement on October 2, 2026, providing details about a securities offering with the SEC.
Lexaria Bioscience files to sell 923,827 shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 923,827 shares of common stock. The company is not selling any…
Lexaria Bioscience updates financial position
Lexaria Bioscience (LEXX) said it is in a strong cash position following both its recently announced Australian tax refund and recent institutional financing priced at $12.92/share. The combined net p...
Lexaria Updates Financial Position
Kelowna, British Columbia – September 17, 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is providing the follo...
Lexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds
Kelowna, British Columbia – September 9, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its previ...
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
KELOWNA, BC / ACCESS Newswire / September 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously anno...
Lexaria Bioscience announces exercise of warrants for $5.9M in proceeds
Lexaria Bioscience (LEXX)s announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company’s common ...
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
KELOWNA, BC / ACCESS Newswire / September 8, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced th...
Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds
Kelowna, British Columbia – TheNewswire - September 8 , 2026 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announce...
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
KELOWNA, BC / ACCESS Newswire / September 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will part...
Lexaria Bioscience receives $2.6M tax rebate payment
Lexaria Bioscience (LEXX) has received a cash rebate of AUD$3,666,611.98 from the Australian Tax Office. The funds were deposited into the bank account of Lexaria’s wholly-owned Australian subsidiary ...
Lexaria Receives USD$2.6 Million Tax Rebate Payment
Lexaria's 2025 Australian human study results in a USD$2.6 million cash rebate KELOWNA, BC / ACCESS Newswire / September 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), ...
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation incr...
Lexaria Bioscience enters MTA with PegBio
Lexaria Bioscience (LEXX) announces that it has entered into a Material Transfer Agreement, MTA, with Pegbio to investigate Lexaria’s DehydraTECH technology with a proprietary PegBio molecule under de...
Lexaria Enters a Material Transfer Agreement With PegBio
KELOWNA, BC / ACCESS Newswire / August 13, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into...